{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:19:29Z","timestamp":1790295569828,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jaut.2017.07.004","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T10:15:14Z","timestamp":1499854514000},"page":"103-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"special_numbering":"C","title":["Novel therapeutic targets for inflammatory bowel disease"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9867-8861","authenticated-orcid":false,"given":"Marjorie","family":"Argollo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Hindryckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9573","key":"10.1016\/j.jaut.2017.07.004_bib1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(07)60750-8","article-title":"Inflammatory bowel disease: cause and immunobiology","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2017.07.004_bib2","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2004.01.063","article-title":"Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences","volume":"126","author":"Loftus","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2017.07.004_bib3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.MIB.0000195385.19268.68","article-title":"Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities","volume":"12","author":"Hanauer","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"issue":"40","key":"10.1016\/j.jaut.2017.07.004_bib4","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.3748\/wjg.v16.i40.5024","article-title":"Health related quality of life in inflammatory bowel disease: the impact of surgical therapy","volume":"16","author":"Umanskiy","year":"2010","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.jaut.2017.07.004_bib5","doi-asserted-by":"crossref","first-page":"G716","DOI":"10.1152\/ajpgi.00472.2010","article-title":"Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease","volume":"300","author":"Danese","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.jaut.2017.07.004_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3748\/wjg.14.390","article-title":"Immunopathogenesis of inflammatory bowel disease","volume":"14","author":"Shih","year":"2008","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","article-title":"Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies","volume":"17","author":"Kim","year":"2017","journal-title":"Immune Netw."},{"issue":"3","key":"10.1016\/j.jaut.2017.07.004_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.jaut.2017.07.004_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000443131","article-title":"\u201cTreat to target\u201d - lessons learnt","volume":"34","author":"Kurti","year":"2016","journal-title":"Dig. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2017.07.004_bib10","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib11","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.08.003","article-title":"Converging goals of treatment of inflammatory bowel disease from clinical trials and practice","volume":"148","author":"Levesque","year":"2015","journal-title":"Gastroenterology"},{"issue":"7351","key":"10.1016\/j.jaut.2017.07.004_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jaut.2017.07.004_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jaut.2017.07.004_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/581631","article-title":"Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update","volume":"2013","author":"Guo","year":"2013","journal-title":"Biomed. Res. Int."},{"issue":"9317","key":"10.1016\/j.jaut.2017.07.004_bib15","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2017.07.004_bib16","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9","key":"10.1016\/j.jaut.2017.07.004_bib17","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jaut.2017.07.004_bib18","first-page":"317","article-title":"Adalimumab in the treatment of moderate-to-severe ulcerative colitis: ULTRA 2 trial results","volume":"9","author":"Sandborn","year":"2013","journal-title":"Gastroenterol. Hepatol. (N. Y.)"},{"issue":"3","key":"10.1016\/j.jaut.2017.07.004_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jaut.2017.07.004_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2017.07.004_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J.\u00a0Crohn's Colitis"},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib23","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.jaut.2017.07.004_bib24","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.jaut.2017.07.004_bib25","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/14712598.2016.1203897","article-title":"Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease","volume":"16","author":"Pouillon","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib26","first-page":"1","article-title":"NIH public access","volume":"23","author":"Manuscript","year":"2008","journal-title":"Growth Lakel."},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib27","first-page":"590","article-title":"NIH public access","volume":"27","author":"Hasson","year":"2009","journal-title":"Mot. Control"},{"issue":"10","key":"10.1016\/j.jaut.2017.07.004_bib28","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/gut.2006.115402","article-title":"The IL23 axis plays a key role in the pathogenesis of IBD","volume":"56","author":"McGovern","year":"2007","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib29","first-page":"27","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"13","author":"Balzola","year":"2012","journal-title":"Inflamm. Bowel Dis. Monit."},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nm0107-26","article-title":"IL-23: a master regulator in Crohn disease","volume":"13","author":"Neurath","year":"2007","journal-title":"Nat. Med."},{"issue":"5804","key":"10.1016\/j.jaut.2017.07.004_bib31","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A\u00a0genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jaut.2017.07.004_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1756283X10374216","article-title":"Review of the safety and efficacy of ustekinumab","volume":"3","author":"Scherl","year":"2010","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06670.x","article-title":"Development of the IL-12\/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives - an update","volume":"1263","author":"Yeilding","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/14712591003724670","article-title":"The use of ustekinumab in autoimmune disease","volume":"10","author":"Ryan","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jaut.2017.07.004_bib35","series-title":"Ustekinumab in Treatment of Crohn\u2019s Disease: Design, Development, and Potential Place in Therapy","first-page":"3685","author":"L","year":"2016"},{"issue":"16","key":"10.1016\/j.jaut.2017.07.004_bib36","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"20","key":"10.1016\/j.jaut.2017.07.004_bib37","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of ustekinumab, a human Interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib39","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","article-title":"Selective targeting of the IL23 pathway: generation and characterization of a novel highaffinity humanized anti-IL23A antibody","volume":"7","author":"Singh","year":"2015","journal-title":"MAbs"},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(15)30547-3","article-title":"830 initial evaluation of MEDI2070 (specific anti-IL-23 antibody) in patients with active Crohn's disease who have failed anti-TNF antibody therapy: a randomized, double-blind placebo-controlled phase 2A induction study","volume":"148","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib41","doi-asserted-by":"crossref","first-page":"S1266","DOI":"10.1016\/S0016-5085(16)34278-0","article-title":"Efficacy and safety of induction therapy with the selective IL-23 inhibitor BI 655066, in patients with moderate-to-severe Crohn's disease: results of a randomized, double-blind, placebo-controlled phase II study (abstract)","volume":"150","author":"Feagan","year":"2016","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jaut.2017.07.004_bib42","first-page":"438","article-title":"The present and future of inflammatory bowel disease treatment","volume":"12","author":"WJ","year":"2016","journal-title":"Gastroenterol. Hepatol. (N. Y.)"},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib43","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","article-title":"Antitumor and antimetastatic activity of interleukin 12 against murine tumors","volume":"178","author":"Brunda","year":"1993","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.jaut.2017.07.004_bib44","doi-asserted-by":"crossref","unstructured":"Feagan BG, Sandborn WJ, Haens GD, Pan\u00e9s J, Kaser A, Ferrante M, et\u00a0al. Articles Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn \u2019 s disease: a randomised, double-blind, placebo-controlled phase 2 study. 2017;6736(17):1\u201311.","DOI":"10.1016\/S0140-6736(17)30570-6"},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756283X10373176","article-title":"Anti-adhesion molecule therapy for inflammatory bowel disease","volume":"3","author":"Ghosh","year":"2010","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"12","key":"10.1016\/j.jaut.2017.07.004_bib46","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.2174\/13894501113149990158","article-title":"Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease","volume":"14","author":"Bamias","year":"2013","journal-title":"Curr. Drug Targets"},{"issue":"8","key":"10.1016\/j.jaut.2017.07.004_bib47","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMe1307415","article-title":"Inhibition of leukocyte trafficking in inflammatory bowel disease","volume":"369","author":"Cominelli","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jaut.2017.07.004_bib48","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J.\u00a0Crohn's Colitis"},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jaut.2017.07.004_bib50","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"9573","key":"10.1016\/j.jaut.2017.07.004_bib51","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jaut.2017.07.004_bib52","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jaut.2017.07.004_bib53","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jaut.2017.07.004_bib54","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jaut.2017.07.004_bib55","first-page":"1","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","author":"Colombel","year":"2016","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.jaut.2017.07.004_bib56","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.10.041","article-title":"Association between response to etrolizumab and expression of integrin \u03b1e and granzyme a in colon biopsies of patients with ulcerative colitis","volume":"150","author":"Tew","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2017.07.004_bib57","doi-asserted-by":"crossref","unstructured":"Pathogens S. HHS public Access. 2016;1848(1):3047\u20133054.","DOI":"10.1016\/j.bbamem.2015.02.010"},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib58","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1177\/1756283X16647935","article-title":"The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes","volume":"9","author":"Fiorino","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"8","key":"10.1016\/j.jaut.2017.07.004_bib59","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A\u00a0randomised phase I study of etrolizumab (rhuMAb \u03b27) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"issue":"9940","key":"10.1016\/j.jaut.2017.07.004_bib60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jaut.2017.07.004_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005720","article-title":"A\u00a0small molecule, which competes with MAdCAM-1, activates integrin \u03b14\u03b27 and fails to prevent mucosal transmission of SHIV-SF162P3","volume":"12","author":"Arrode-Brus\u00e9s","year":"2016","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.jaut.2017.07.004_bib62","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrd.2015.10","article-title":"Integrin-based therapeutics: biological basis, clinical use and new drugs","volume":"15","author":"Ley","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"17","key":"10.1016\/j.jaut.2017.07.004_bib63","first-page":"1","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"6736","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2017.07.004_bib64","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/bph.12134","article-title":"Pharmacology of AMG 181, a human anti-\u03b14\u03b27 antibody that specifically alters trafficking of gut-homing T cells","volume":"169","author":"Pan","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib65","doi-asserted-by":"crossref","first-page":"e00098","DOI":"10.1002\/prp2.98","article-title":"Prediction of clinical pharmacokinetics of AMG 181, a human anti- \u03b1 4 \u03b2 7 monoclonal antibody for treating inflammatory bowel diseases","volume":"3","author":"Li","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"issue":"6","key":"10.1016\/j.jaut.2017.07.004_bib66","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/bcp.12418","article-title":"Clinical pharmacology of AMG 181, a gut-specific human anti-\u03b14\u03b27 monoclonal antibody, for treating inflammatory bowel diseases","volume":"78","author":"Pan","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jaut.2017.07.004_bib67","first-page":"1","article-title":"Next generation of small molecules in inflammatory bowel disease","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.jaut.2017.07.004_bib68","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.gtc.2014.05.011","article-title":"Update on janus kinase antagonists in inflammatory bowel disease","volume":"43","author":"Boland","year":"2014","journal-title":"Gastroenterol. Clin. N. Am."},{"issue":"1","key":"10.1016\/j.jaut.2017.07.004_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.jaut.2017.07.004_bib70","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","author":"Danese","year":"2015","journal-title":"Am. J. Physiol. - Gastrointest. Liver Physiol."},{"issue":"7","key":"10.1016\/j.jaut.2017.07.004_bib71","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"10","key":"10.1016\/j.jaut.2017.07.004_bib72","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.jaut.2017.07.004_bib73","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjx003","article-title":"The future of janus kinase inhibitors in inflammatory bowel disease","author":"De Vries","year":"2017","journal-title":"J.\u00a0Crohns Colitis"},{"key":"10.1016\/j.jaut.2017.07.004_bib74","series-title":"Presentation OP021. Efficacy and Safety of Oral Tofacitinib for Induction Therapy in Patients with Moderate-to-severe Crohn's Disease: Results of a Phase 2b Randomised Placebo- Controlled Trial","author":"Pan\u00e9s","year":"2016"},{"key":"10.1016\/j.jaut.2017.07.004_bib75","series-title":"Presentation OP022. Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients with Moderate-to-severe Crohn's Disease: Results of a Phase 2b Randomised Pla- Cebo-controlled Trial","author":"D'Haens","year":"2016"},{"issue":"9","key":"10.1016\/j.jaut.2017.07.004_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A\u00a0phase 2 study of Tofacitinib, an oral janus kinase inhibitor, inpatients with crohn's disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jaut.2017.07.004_bib77","first-page":"32538","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib [the FITZ- ROY study]: results from a phase 2, double-blind, randomised, placebo- controlled trial","volume":"16","author":"Vermeire","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2017.07.004_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"18","key":"10.1016\/j.jaut.2017.07.004_bib79","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jaut.2017.07.004_bib80","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/1756283X16636781","article-title":"Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn disease","volume":"9","author":"Ardizzone","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"12","key":"10.1016\/j.jaut.2017.07.004_bib81","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117304213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841117304213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:17:27Z","timestamp":1760257047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841117304213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":81,"alternative-id":["S0896841117304213"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2017.07.004","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutic targets for inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2017.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}